Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKBR | P32239 | 3/20 | 0.40 |
| ▸ | NMUR2 | Q9GZQ4 | 9/20 | 0.38 |
| ▸ | NMUR1 | Q9HB89 | 4/20 | 0.38 |
| ▸ | MC4R | P32245 | 2/20 | 0.34 |
| ▸ | TTR | P02766 | 1/20 | 0.34 |
| ▸ | IL2 | P60568 | 1/20 | 0.34 |
| ▸ | CCKAR | P32238 | 1/20 | 0.33 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.33 |
| ▸ | PLG | P00747 | 1/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.33 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.33 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.33 |
| ▸ | APLNR | P35414 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12377406 | 0.96 | CCKBR (0.39) | CCKBRNMUR2NMUR1TTRIL2 | |
| SCHEMBL12342513 | 0.91 | OPRK1 (0.39) | CCKBRNMUR2NMUR1TTRIL2 | |
| SCHEMBL14129393 | 0.91 | OPRK1 (0.39) | CCKBRNMUR2NMUR1TTRIL2 | |
| SCHEMBL12342493 | 0.87 | OPRK1 (0.40) | CCKBRNMUR2NMUR1TTRIL2 | |
| SCHEMBL14329043 | 0.84 | CCKBR (0.39) | CCKBRNMUR2NMUR1MC4RTTR | |
| SCHEMBL12342504 | 0.80 | TTR (0.44) | CCKBRNMUR2NMUR1TTRIL2 | |
| SCHEMBL22969740 | 0.79 | TTR (0.38) | NMUR2NMUR1TTRIL2FOLH1 | |
| SCHEMBL25795469 | 0.78 | CCKBR (0.35) | CCKBRFOLH1PLGPRSS1PRSS2 | |
| SCHEMBL13684278 | 0.77 | TTR (0.41) | TTRIL2FOLH1 | |
| SCHEMBL31681640 | 0.76 | TTR (0.44) | CCKBRTTRIL2FOLH1PLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312736-A1 | ANTIBODIES AND FUSION PROTEINS THAT BIND TO CCR8 AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-10-05 | — | — | US | disclosed |
| US-11692038-B2 | Antibodies that bind chemokine (C-C motif) receptor 8 (CCR8) | GILEAD SCIENCES, INC. (US) | 2023-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312736-A1 | ANTIBODIES AND FUSION PROTEINS THAT BIND TO CCR8 AND USES THEREOF | CCR8, CCR4, CCR3 | CCKBR 2152/4885NMUR2 2953/4885NMUR1 2734/4885 |
| US-11692038-B2 | Antibodies that bind chemokine (C-C motif) receptor 8 (CCR8) | CCR8, CCR1, CCR3 | CCKBR 669/4885NMUR2 2630/4885NMUR1 2358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.